Business
Currency:EUR
2024/Q2
Stock NameRevenueRatio
Research and development of T cell redirecting immunotherapies for the treatment of cancer18.76M100.00%
Region
Currency:EUR
2023/FY
Stock NameRevenueRatio
BMS, United States50.7M93.88%
Moderna, United States5.37M9.94%
Genmab, Denmark-2.07M-3.83%